Herbs (Global Traditional) · African
Combretum micranthum
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Combretum micranthum is an African medicinal plant containing flavonoids and phenolic compounds that demonstrate antihypertensive properties. The extract works through ACE inhibition and diuretic mechanisms to support cardiovascular health.
Combretum micranthum, commonly known as kinkeliba or kinkéliba, is a shrub or small tree native to sub-Saharan Africa, particularly West Africa, belonging to the Combretaceae family. It is primarily sourced from its leaves, which are used in traditional preparations including decoctions, tablets, and ethanolic or aqueous extracts.
A multicenter randomized controlled trial in Senegal (n=219 hypertensive patients) compared kinkeliba tablets (400 mg/day) or brew (10 g leaves/day) to captopril over 6 months, showing comparable efficacy for blood pressure reduction (PMID: 32948827). No other human clinical trials were identified, with remaining evidence limited to preclinical in vitro and ex vivo studies examining nephroprotection, antioxidant, and anti-inflammatory mechanisms.
Clinically studied doses: Tablets at 400 mg/day (2 × 200 mg) or leaf decoction at 10 g/day, administered for 6 months for hypertension. No standardization for polyphenol content was specified in clinical trials. Consult a healthcare provider before starting any new supplement.
Combretum micranthum (kinkeliba) leaves are consumed primarily as a tisane rather than a caloric food source, so macronutrient contribution is negligible per typical serving. Key bioactive compounds and micronutrient considerations include: **Polyphenols & Flavonoids:** Total phenolic content reported at approximately 45–85 mg gallic acid equivalents (GAE) per gram of dry leaf extract, depending on extraction method. Major flavonoids include vitexin (4′,5,7-trihydroxyflavone-8-glucoside, ~2–5 mg/g dry weight), isovitexin (~1–3 mg/g), orientin, and isoorientin (C-glycosylflavones). Myricetin-3-O-glucoside and myricetin-3-O-rhamnoside have been identified at lower concentrations (~0.5–2 mg/g). **Tannins:** Contains condensed tannins (proanthocyanidins) and hydrolyzable tannins (notably combreglutinin, a unique ellagitannin), estimated at 5–12% of dry leaf weight. These contribute to astringency and may reduce bioavailability of co-consumed iron and proteins. **Alkaloids:** Contains trace amounts of stachydrine (proline betaine) and choline-derived alkaloids (~0.1–0.5% dry weight), which may contribute to hepatoprotective and diuretic effects. **Triterpenoids & Saponins:** Cycloartane-type triterpenoids and oleanolic acid derivatives detected; concentrations not precisely quantified but estimated at 0.5–2% of dry extract. **Minerals (per dry leaf):** Potassium (~15–22 mg/g), calcium (~8–15 mg/g), magnesium (~3–6 mg/g), iron (~0.2–0.5 mg/g), zinc (~0.03–0.08 mg/g), and manganese (~0.05–0.15 mg/g). Mineral bioavailability in aqueous infusions is moderate but may be reduced by tannin-mineral chelation. **Vitamins:** Modest amounts of ascorbic acid (~5–15 mg/100 g dry leaf) have been reported; B-vitamins present in trace quantities. **Fiber & Protein (whole leaf):** Crude fiber ~15–22% and crude protein ~8–12% of dry weight, though these are largely unextracted in typical tea preparations. **Antioxidant capacity:** ORAC values of aqueous extracts reported at approximately 150–300 µmol Trolox equivalents per gram dry extract. DPPH radical scavenging IC50 values range from 5–25 µg/mL for methanolic extracts. **Bioavailability notes:** C-glycosylflavones (vitexin, orientin) are relatively stable through gastrointestinal passage compared to O-glycosides, with moderate absorption; however, significant microbial metabolism in the colon produces smaller phenolic acids that may contribute to systemic bioactivity. Tannin content may limit mineral and protein absorption when consumed with meals. Aqueous infusion (traditional preparation) extracts approximately 30–50% of total polyphenols from dried leaves.
Combretum micranthum exerts its antihypertensive effects primarily through angiotensin-converting enzyme (ACE) inhibition by its flavonoid compounds, particularly quercetin and kaempferol derivatives. The extract also demonstrates mild diuretic activity, increasing sodium and water excretion. Additional nephroprotective mechanisms include antioxidant activity that reduces oxidative stress in renal tissues exposed to hyperglycemic conditions.
The primary clinical evidence comes from one randomized controlled trial demonstrating significant antihypertensive effects. In this study, 65% of patients achieved clinically significant systolic blood pressure reduction of ≥10 mmHg, with 51% reaching target blood pressure <140/90 mmHg. Preclinical studies have shown nephroprotective effects against high-glucose cytotoxicity in kidney cells. However, the clinical evidence base remains limited, requiring larger, longer-duration trials to establish comprehensive safety and efficacy profiles.
Combretum micranthum appears well-tolerated in clinical studies with no serious adverse events reported. However, its ACE-inhibiting properties may potentiate the effects of antihypertensive medications, particularly ACE inhibitors and diuretics, potentially causing excessive blood pressure reduction. Patients taking blood pressure medications should consult healthcare providers before use. Safety during pregnancy and lactation has not been established, and use should be avoided in these populations.
